|
Volumn 17, Issue 2, 2002, Pages 219-231
|
Actinium-225 conjugates of MAb CC49 and humanized ΔCH2CC49
a b b b a |
Author keywords
HEHA; MAb CC49; Micro distribution; Radiotoxicity; Therapy
|
Indexed keywords
1,4,7,10,13,16 HEXAAZACYCLOOCTADECANE N,N',N'',N''',N'''',N''''' HEXAACETIC ACID;
ACTINIUM;
ACTINIUM 1,4,7,10,13,16 HEXAAZACYCLOOCTADECANE N,N',N'',N''',N'''',N''''' HEXAACETIC ACID MONOCLONAL ANTIBODY CC49 AC 225;
ACTINIUM 1,4,7,10,13,16 HEXAAZACYCLOOCTADECANE N,N',N'',N''',N'''',N''''' HEXAACETIC ACID MONOCLONAL ANTIBODY HU CC49 AC 225;
CHELATING AGENT;
DRUG CARRIER;
IODINE 1,4,7,10,13,16 HEXAAZACYCLOOCTADECANE N,N',N'',N''',N'''',N''''' HEXAACETIC ACID HU CC49 I 125;
IODINE 1,4,7,10,13,16 HEXAAZACYCLOOCTADECANE N,N',N'',N''',N'''',N''''' HEXAACETIC ACID MONOCLONAL ANTIBODY CC49 I 125;
IODINE 125;
MONOCLONAL ANTIBODY CC49;
UNCLASSIFIED DRUG;
ALPHA RADIATION;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
AUTORADIOGRAPHY;
CANCER THERAPY;
CELL GROWTH;
COLON ADENOCARCINOMA;
CONTROLLED STUDY;
DRUG CONJUGATION;
DRUG DISTRIBUTION;
DRUG EXTRAVASATION;
DRUG HALF LIFE;
DRUG PENETRATION;
DRUG RETENTION;
DRUG TARGETING;
DRUG TISSUE LEVEL;
IMMUNE DEFICIENCY;
ISOTOPE LABELING;
LETHAL DOSE;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
RADIOIMMUNOTHERAPY;
RADIOISOTOPE DECAY;
TREATMENT OUTCOME;
ACTINIUM;
ALPHA PARTICLES;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTINEOPLASTIC AGENTS;
HUMANS;
MICE;
MICE, INBRED ICR;
MICE, NUDE;
MICE, SCID;
NEOPLASMS, EXPERIMENTAL;
RADIOIMMUNOTHERAPY;
RADIOTHERAPY DOSAGE;
TISSUE DISTRIBUTION;
|
EID: 0036248529
PISSN: 10849785
EISSN: None
Source Type: Journal
DOI: 10.1089/108497802753773847 Document Type: Article |
Times cited : (26)
|
References (31)
|